Drugs / peg-IFN alpha
peg-IFN alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04640129 | Jan 2021 → Nov 2025 | fibrotic liver disease | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-06-24 | Vir Biotechnology, Inc. | Results Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D vir.bio ↗
16% (5/31) achieved sustained HBsAg loss 24 weeks following the end of treatment. |
| 2022-11-06 | Vir Biotechnology, Inc. | Results Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection vir.bio ↗
Additionally, 48 weeks of VIR-2218 plus PEG-IFN-α provided greater reductions in hepatitis B surface antigen (HBsAg) (mean decrease of -2.9 log10 IU/mL) compared to VIR-2218 alone or with shorter regimens of the combination. |
| 2021-11-12 | Vir Biotechnology, Inc. | Results Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting® vir.bio ↗
New findings also demonstrate that concurrent initiation of VIR-2218 and pegylated interferon alpha (PEG-IFN-α) therapy resulted in substantial HBsAg reductions compared to VIR-2218 alone or with PEG-IFN-α following a VIR-2218 lead-in. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peg-IFN alpha | “INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen...” PMID 34697111 ↗ Oct 2021 |
| Known as | peg-IFN-α | “As another anti-HBV drug, pegylated-interferon-α (peg-IFN-α) has the immune regulation effect that NAs do not have” NCT04640129 ↗ |
| Known as | PEG-Interferon Alfa | “Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy” NCT04640129 ↗ |
| Known as | pegylated interferon alpha | “INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen...” PMID 34697111 ↗ Oct 2021 |
| Route | Subcutaneous | “Participants in the combination group will receive subcutaneous injections of peg-IFN alpha 180 µg per week for 48 weeks” PMID 34697111 ↗ Oct 2021 |